Patents Examined by Layla Soroush
-
Patent number: 11970476Abstract: A 6?-(4-chlorophenyl)-2?-alkoxy-3,4?-bipyridine-3?-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: October 11, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11957685Abstract: Liquid pharmaceutical compositions of tofacitinib or its pharmaceutically acceptable salts thereof are described, which are suitable for oral administration, and which are stable under varying storage conditions for extended periods of time. Methods of treating auto-immune disorders are also described, using the stable liquid pharmaceutical compositions of tofacitinib. A stable liquid pharmaceutical composition of tofacitinib according to the invention comprises of (a) tofacitinib at a concentration of about 1 mg/mL or more; (b) a pharmaceutically acceptable liquid vehicle; (c) at least one anti-oxidant; and (d) optionally one or more other pharmaceutically acceptable excipients.Type: GrantFiled: August 10, 2023Date of Patent: April 16, 2024Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Sumitra Ashokkumar Pillai
-
Patent number: 11938118Abstract: An analgesic and antipruritic pharmaceutical composition, including PF-05089771 shown as and PF-04885614 shown as An application of the analgesic and antipruritic pharmaceutical composition in the treatment of a disease in which both a voltage-gated sodium channel 1.7 (Nav1.7) and a voltage-gated sodium channel 1.8 (Nav1.8) are involved.Type: GrantFiled: February 20, 2023Date of Patent: March 26, 2024Assignee: SHANGHAI RUIHUKANG PHARMACEUTICAL PARTNERSHIP (LIMITED PARTNERSHIP)Inventors: Changgeng Peng, Liting Sun, Ruilong Xia
-
Patent number: 11931326Abstract: Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.Type: GrantFiled: July 8, 2022Date of Patent: March 19, 2024Assignee: DIET SHIELD LTDInventors: Andrew Kitchner, Denis Carr
-
Patent number: 11931370Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.Type: GrantFiled: October 7, 2022Date of Patent: March 19, 2024Assignee: SLAYBACK PHARMA LLCInventors: Shailendra Mandge, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
-
Patent number: 11918572Abstract: A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.Type: GrantFiled: January 27, 2023Date of Patent: March 5, 2024Assignee: REBEL MEDICINE INCInventors: Brett Hale Davis, Caleb Adrian Lade, Sierra Nichelle Erickson, Susan Alice Wojtalewicz
-
Patent number: 11890265Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.Type: GrantFiled: March 25, 2019Date of Patent: February 6, 2024Assignee: SERBIG PHARMACEUTICALS CORPORATIONInventor: Pedro Anastacio Serrano-Ojeda
-
Patent number: 11872305Abstract: The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or ?-? unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.Type: GrantFiled: August 26, 2022Date of Patent: January 16, 2024Inventors: Ashish Anilrao Dubewar, Amit Anil Charkha, Sumitra Ashokkumar Pillai, Pradeep Kumar Kare, Kumar Swamy Ummiti, Shanker Mamidi, Mayur Anshiram Adhav
-
Patent number: 11844836Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.Type: GrantFiled: October 16, 2020Date of Patent: December 19, 2023Assignee: DERMALIQ THERAPEUTICS, INC.Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
-
Patent number: 11844782Abstract: An aqueous composition includes either dantrolene or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative, with the pH of the aqueous composition greater than 7. A powder can be obtained by drying the composition. The powder can be included in a kit.Type: GrantFiled: October 19, 2016Date of Patent: December 19, 2023Assignee: SPEPHARM AGInventors: Hervé Jean Schwebel, Vincent Adamo
-
Patent number: 11840732Abstract: A method for determining one or more tumour properties in a subject with a tumour, the method comprising:—seeding a cell-free scaffold obtained from the tumour with cancer cells;—culturing the cancer cells in the scaffold;—assaying the cultured cancer cells for the presence of target molecules indicative of the expression of one or more genes in the cells; and—determining one or more tumour properties based on the results of the assay.Type: GrantFiled: November 3, 2017Date of Patent: December 12, 2023Assignee: ISCAFF PHARMA ABInventors: Göran Landberg, Anders Ståhlberg, Joakim Håkansson
-
Patent number: 11813250Abstract: A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.Type: GrantFiled: September 2, 2022Date of Patent: November 14, 2023Assignee: SHANGHAI AUCTA PHARMACEUTICALS CO., LTD.Inventors: Shoufeng Li, Yi Zhao, Qiaolin Ren
-
Process for increasing the stability of a composition comprising polyunsaturated omega-3 fatty acids
Patent number: 11805798Abstract: A solid product composition includes at least one salt of a cation derived from lysine with an anion derived from a polyunsaturated omega-3 fatty acid. The solid product composition is formed by (i) providing a starting composition containing at least one polyunsaturated omega-3 fatty acid component; (ii) providing a lysine composition; and (iii) admixing an aqueous, an aqueous-alcoholic or an alcoholic solution of starting composition and lysine composition, and subjecting resulting admixture to spray drying conditions subsequently, thus forming the solid product composition containing at least one salt of a cation derived from lysine with an anion derived from a polyunsaturated omega-3 fatty acid.Type: GrantFiled: August 18, 2020Date of Patent: November 7, 2023Assignee: Evonik Operations GmbHInventors: Günter Knaup, Milan Latinovic, Michael Schwarm -
Patent number: 11806334Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.Type: GrantFiled: January 12, 2023Date of Patent: November 7, 2023Assignee: BioXcel Therapeutics, Inc.Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Lavanya Rajachandran, Robert Risinger
-
Patent number: 11786514Abstract: A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.Type: GrantFiled: June 22, 2022Date of Patent: October 17, 2023Inventors: Sean Cunningham, Seamus Mulligan, Michael Myers
-
Patent number: 11786597Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.Type: GrantFiled: June 21, 2019Date of Patent: October 17, 2023Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, TRIAD NATIONAL SECURITY, LLC, THE ARIZONA BOARD OF REGENTSInventors: Michael Zakrewsky, Samir Mitragotri, David T. Fox, Andrew Koppisch, Rico Del Sesto, Katherine Lovejoy
-
Patent number: 11771675Abstract: The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.Type: GrantFiled: October 7, 2020Date of Patent: October 3, 2023Assignee: ORION CORPORATIONInventors: Juha Rouru, Mikko Kuoppamäki, Juha Ellmen, Pekka Männistö
-
Patent number: 11771682Abstract: A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.Type: GrantFiled: November 26, 2019Date of Patent: October 3, 2023Assignee: Ellipses Pharma Ltd.Inventors: Gary Hattersley, Jamal Saeh, Ziyang Yu, Chris Miller, Teeru Bihani
-
Patent number: 11766435Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: GrantFiled: February 13, 2017Date of Patent: September 26, 2023Assignees: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Patent number: 11766438Abstract: The present invention relates to liquid pharmaceutical compositions of tofacitinib or its pharmaceutically acceptable salts thereof, suitable for oral administration, that are stable under varying storage conditions for extended periods of time. The present invention also relates to methods of treating auto-immune disorders using the stable liquid pharmaceutical compositions of tofacitinib. A stable liquid pharmaceutical composition of tofacitinib according to the invention comprises of (a) tofacitinib at a concentration of about 1 mg/mL or more; (b) a pharmaceutically acceptable liquid vehicle; (c) at least one anti-oxidant; and (d) optionally one or more other pharmaceutically acceptable excipients.Type: GrantFiled: April 23, 2021Date of Patent: September 26, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Sumitra Ashokkumar Pillai